1. 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours. (15th December 2019) Authors: Reck, M; Cappuzzo, F; Rodriguez-Abreu, D; Cho, D C; Schwarz, J K; Riese, M J; Gupta, A; Chan, T; Saab, R; Singel, S; Lin, W; Tagliaferri, M; Spigel, D R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗